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Abstract
Aims To determine the proportion of people with diabetes who have HbA1c measured, what proportion achieve an
HbA1c level of < 58 mmol/mol (7.5%), the frequency of testing and if there was any change in HbA1c level in the year
before and the year after an incident stroke.
Methods This study used the Secure Anonymised Information Linkage (SAIL) databank, which stores hospital data for
the whole of Wales and ~ 65% of Welsh general practice records, to identify cases of stroke in patients with diabetes
between 2000 and 2010. These were matched against patients with diabetes but without stroke disease. We assessed the
frequency of HbA1c testing and change in HbA1c in the first year after stroke. Estimation was made of the proportion of
patients achieving an HbA1c measurement ≤ 58 mmol/mol (7.5%).
Results There were 1741 patients with diabetes and stroke. Of these, 1173 (67.4%) had their HbA1c checked before
their stroke and 1137 (65.3%) after their stroke. In the control group of 16 838 patients with diabetes but no stroke,
8413 (49.9%) and 9288 (55.1%) had their HbA1c checked before and after the case-matched stroke date, respectively. In
patients with diabetes and stroke, HbA1c fell from 61–56 mmol/mol (7.7–7.3%) after their stroke (P < 0.001). Before
the study, 55.0% of patients with stroke had an HbA1c ≥ 58 mmol/mol compared with 65.2% of control patients, these
figures were 62.5% and 65.3% after the stroke.
Conclusions The frequency of diabetes testing was higher in patients who had experienced a stroke before and after
their incident stroke compared with control patients but did not increase after their stroke. Glucose control improved
significantly in the year after a stroke.
Diabet. Med. 33, 459–462 (2016)
Introduction
After experiencing a stroke, people with diabetes are more
likely to have another stroke and to have earlier mortality
than those who have not had a stroke [1]. The National
Health and Nutrition Examination Survey study [2] has
shown that, over a period of 9 years (between 1999 and
2008), there was an improvement in several cardiovascular
risk factors including HbA1c in people diagnosed with
diabetes. Diabetes is common in patients with stroke but
guidelines do not give specific recommendations concerning
diabetes management after stroke, either in terms of
frequency of HbA1c testing or blood glucose control. What
level of glycaemic control is achieved after a stroke and
whether lowering of HbA1c levels after a stroke through
aggressive blood glucose control is beneficial is not known
[3].
We aimed to determine the proportion of people with
diabetes who have HbA1c measured, what proportion
achieve an HbA1c level of < 58 mmol/mol (7.5%), the
frequency of testing and if there was any observed change
in HbA1c level in the year before and after an incident stroke.
Methods
The Secure Anonymised Information Linkage (SAIL) data-
bank stores hospital data for the whole of Wales, as well as
for ~ 65% of Welsh general practices [4]. Once a general
practice has voluntarily signed up to SAIL, data submission
are facilitated annually. All historical general practice
records are uploaded and made available for retrospective
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analysis, with patient records being present based on the
period of registration with the given practice. Nationwide
Welsh hospital data are submitted annually to SAIL and
processed by the NHS Wales Informatics Service.
A study window between 2000 and 2010 was used to
select incident cases of stroke in Welsh hospitals, identified
using International Classification of Diseases-10 codes I61
and I64. These individuals were then linked to data available
in general practice records contained within SAIL by an
encrypted National Health Service (NHS) number, where
version 2 READ codes C10 and further subcodes (e.g. C101)
were used to identify patients who had diabetes before their
incident stroke, and READ codes 42W (including subcodes)
and 44 TB, 44TC, 44TL were used to select HbA1c
measurements in the year before and after the incident
stroke. We only included patients who survived at least
1 year after stroke.
A control group was formed by selecting (without
replacement) at least eight patients per case, matched by
age and sex from the Welsh population that had diabetes.
None of the control patients had reported any admission for
stroke.
We determined the frequency of HbA1c testing and change
in HbA1c levels in the first year after stroke, using one-sample
t-tests (unpaired). The frequency group was a subset of the
case–control group where each person survived the first year
after stroke and was registered with a SAIL general practi-
tioner for the years before and after stroke, and the HbA1c
analysis was a subset of the frequency group, where all
persons had at least one HbA1c measurement in the year
before and after stroke. Finally, estimation was made of the
proportion of both cases and controls who achieved an
HbA1c measurement at or below 58 mmol/mol (7.5%).
Results
A total of 1741 patients met our inclusion criteria. Their
mean ( SD) age was 72.3 ( 10.56) years. Of these, 1173
(67.4%) had their HbA1c checked in the year before their
stroke and 1137 (65.3%) after their stroke. In the matched
control group of 16 838 patients with diabetes but no stroke
[mean ( SD) age 72.3 ( 10.27) years], 8413 (49.9%) and
9288 (55.1%) had their HbA1c checked before and after the
case-matched stroke date, respectively.
Patients with diabetes had a higher mean frequency of
HbA1c testing by their general practitioner before an incident
stroke, with no change in frequency in the year after stroke.
The patients with diabetes who had not experienced a stroke
underwent a small increase in frequency of testing. These
results are shown in Table 1.
In those who had experienced a stroke, the HbA1c level
was 4 mmol/mol (0.4%) higher before their stroke compared
with the control group (P < 0.001). A year after the index
stroke, a decrease in HbA1c levels was observed in those in
the case group, in both men and women, compared with the
control group, where no change was observed (Table 2).
In the year before the study commenced, 55.0% of cases
had an HbA1c ≤ 58 mmol/mol (7.5%) compared with
65.2% of controls, with the equivalent figures in the year
after the stroke being 62.5% of cases and 65.3% of controls.
Discussion
Using the SAIL databank we examined diabetes control and
monitoring in a large and generalizable cohort of stroke
survivors. The frequency of diabetes testing was higher in
patients with diabetes who had experienced a stroke before
and after their incident stroke compared with control
patients, but the frequency of testing did not increase after
their stroke. We found glucose control, measured using both
the HbA1c level and the percentage of patients achieving a
target HbA1c level, improved significantly in the year after a
stroke and became similar to that in patients with diabetes
who had not experienced a stroke.
We found that the annual rate of testing was 78% in the
year preceding stroke and 76% in the year after stroke. This
is lower than the UK national audit results for patients with
Type 2 diabetes, where 91.3% had an annual HbA1c in
2011–2012 [5]. The discrepancy may be explained by two
factors. Firstly, we were not able to detect HbA1c measured
in secondary care, a limitation of the SAIL databank. The
national audit estimated secondary care HbA1c measures to
account for just under 4% of their results. Secondly, our
results are from the time period 2006–2010 compared with
the latest national diabetes audit from 2011 to 2012. It is
likely that, partly as a result of the audit itself, the frequency
of testing has increased in this period in the UK as a whole.
Our data support that by showing an increase in HbA1c
testing in the control group.
The patients with diabetes who had experienced a stroke
had a higher baseline rate of testing in the year preceding
their stroke than the control group. This may reflect clinical
concern regarding their HbA1c levels, which we found to be,
on average, 4 mmol/mol (0.4%) higher in the year before
their stroke than those of the control group.
What’s new?
 This is the first description of HbA1c assessment in the
year before and the year after an incident stroke.
 The study considers the Secure Anonymized Informa-
tion Linkage (SAIL) databank, which is a large
epidemiological resource, representative of the Welsh
population.
 HbA1c levels were found to decrease in the year after a
stroke by 4 mmol/mol (0.4%).
 Despite falls in HbA1c levels the frequency of HbA1c
testing did not change in the year after a stroke.
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The rates of HbA1c testing after stroke did not increase.
UK national guidelines recommend monitoring of HbA1c
every 2–6 months in patients with Type 2 diabetes [6]. Our
findings were clearly below these guidelines. There are
several possible explanations. Stroke frequently causes dis-
ability and reduced healthcare access, meaning that HbA1c
testing may not be easily available for all. Additionally, in
those people with major disability, or those who receive end-
of-life care, frequent HbA1c monitoring may not be indicated
We also aimed to assess change in HbA1c levels after
stroke. We found the HbA1c level was reduced substantially
after a stroke, reaching the same level as in patients without
stroke. A drop of 4 mmol/mol (0.4%) after a stroke will lead
to better diabetic outcomes [7] and indicates an improved
level of diabetes control overall. What level of post-stroke
HbA1c represents the optimum level after a stroke is still to
be determined and warrants future study. The present study
only considered HbA1c levels in patients who survived for
1 year after stroke and not in those who died; therefore, this
finding is more likely to represent improved control of
diabetes rather than a higher premorbid HbA1c level in
patients who died from their stroke.
The national audit of diabetes care, which has already been
discussed, showed that 65.8% of patients tested had an
HbA1c level within the 58 mmol/mol (7.5%) range or lower.
This level reflects the definition of adequate control levels set
by UK guidelines [6]. To aid comparison, the present study
used this threshold. There was a marked rise in the number
of patients with diabetes achieving this level in the year after
stroke, from 55 to 62.5%, in the present study sample.
Other possible reasons for the levels of HbA1c found are
inadequate monitoring or failure to optimize treatment.
Evidence exists relating to inadequate diabetic control after
stroke. A case–control study was performed comparing 2830
patients with cerebrovascular disease against 24886 patients
without [8]. There were established diagnoses of diabetes in
982 patients in the stroke survivor group and in 5163
patients in the control group. A total of 895 patients (88.3%)
in the stroke survivor group were receiving treatment, but
only 59.2% of this group had adequate control.
Post-stroke HbA1c levels may also be affected by certain
factors directly related to stroke disease itself. Empowering
patients, through knowledge, can help individuals take
control of their diabetes management [9]. In people with
cognitive impairment after stroke this is likely to be more
challenging and to contribute to inadequate risk factor
control. Carers or family members are relied upon in this
situation to help encourage and monitor medication concor-
dance, promote lifestyle advice and support access to
healthcare professionals.
In the present examination of a large national database, we
found that HbA1c levels improved in people who had a
stroke. It appeared that these individuals represented a high-
risk population before their stroke, with a higher baseline
frequency of HbA1c testing, which did not change. The
degree of HbA1c testing was substantially below the recom-
mended UK guidelines. Future studies should consider HbA1c
levels in patients with diabetes who have had a stroke who
are left severely disabled after their stroke to assess whether
the improvement in HbA1c level and static level of testing
Table 1 The annual frequency of HbA1c testing in the year preceding and the year following an incident stroke
Year before Year after
P NNumber Measured Mean frequency Number Measured Mean frequency
Case group 1173 1.36 1137 1.35 0.91 1741
Men 676 1.41 651 1.41 0.90 978
Women 497 1.30 486 1.28 0.75 763
Control group 8413 1.03 9288 1.14 < 0.001 16838
Men 4474 1.05 4917 1.17 < 0.001 8745
Women 3939 1.00 4371 1.10 < 0.001 8093
Table 2 Average HbA1c measurements before and after incident stroke
Mean HbA1c, mmol/mol (%)
P NBefore After Mean difference (95% CI)
Case group 61 (7.7) 56 (7.3) 0.38 (0.46, 0.29) < 0.001 1007
Men 60 (7.6) 56 (7.3) 0.38 (0.49, 0.28) < 0.001 582
Women 61 (7.8) 57 (7.4) 0.36 (0.5, 0.2) < 0.001 425
Control group 56 (7.3) 56 (7.3) 0.01 (0.03, 0.01) 0.47 7703
Men 56 (7.3) 56 (7.3) 0.01 (0.03, 0.01) 0.48 4118
Women 56 (7.3) 56 (7.3) 0 (0.03, 0.02) 0.76 3585
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observed in the present study were influenced by the
healthcare needs of this group of stroke survivors.
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